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Abstract
The biosynthesis of prostaglandins and thromboxanes 
has been a focus of interest in the management of 
many liver diseases. Cyclooxygenases are the enzymes 
involved in the first step of the biosynthesis of these 
lipid mediators and selective inhibitors for these 
isoenzymes as well as pharmacological analogues 
of prostaglandins have been developed and are 
currently applied therapeutically. Here we discuss the 
implications of these enzymes in the onset of metabolic 
and lipid disorders in the liver and their potential role 
in the progression of the diseases towards fibrosis and 
hepatocellular carcinogenesis.
Key words: Cyclooxygenase-2; NAS; Prostaglandin; Non-
alcoholic steatohepatitis; Hepatocellular carcinoma
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Core tip: The assessment of the role of Cyclooxygenase-2 
(COX-2) in hepatic diseases, ranging from non-alcoholic 
steatohepatitis to hepatocellular carcinoma, constitutes a 
field in which controversy exists probably because of the 
use of different experimental models. Since potent and 
selective inhibitors of COX-2 exist, but also stable PGE2 
analogues to be used in therapy, unraveling the precise 
contribution of this enzyme and its products to the 
prevention of the progress of liver dysfunctions appears 
to be a useful approach for managing liver diseases.
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INTRODUCTION
Prostaglandins and thromboxanes are bioactive lipids 
that regulate many physiological responses but in 
some cases are recognized as players in inflammatory 
and tumor diseases, including colorectal and hepatic 
cancer[1,2]. Cyclooxygenase (COX or prostaglandin 
G/H synthase, EC 1.14.99.1) catalyzes the rate-
limiting step in the synthesis of prostaglandins (PGs) 
and thromboxanes using arachidonic acid (AA) as 
substrate to generate PGH2, which is the precursor for a 
number of cell specific prostaglandin and thromboxane 
synthases that generate the biologically active products 
PGE2, PGF2α, PGD2, PGI2 and thromboxanes among 
other bioactive lipids[1]. Various phospholipases cleave 
membrane bound AA that once released, it serves as 
substrate for three main routes: the cyclooxygenase 
(producing PGs and thromboxanes), the lipoxygenase 
(producing lipoxins) and the cytochrome P-450 
monooxygenase pathways. The COX pathway has 
been extensively studied in view of the important 
effects exerted by PGs in many physiological and 
pathological processes. Moreover, this pathway is 
clinically relevant because this enzyme is the main 
target of nonsteroidal anti-inflammatory drugs, and 
selective COX-2 inhibitors are efficient in decreasing 
inflammation, and mitigating pain and fever[3,4]. 
Prostanoids exit the cells via a carrier-mediated process 
to activate specific prostanoids-dependent G protein-
coupled receptors (GPCRs). There are at least eleven 
known PG receptors, all of them belonging to the 
GPCRs superfamily of seven transmembrane spanning 
proteins. For PGE2, EP1 receptors are coupled to Gq 
and activate phospholipase C and increase cytoplasmic 
Ca2+. EP2 and EP4 receptors are coupled to Gs proteins, 
which activate adenylate cyclase leading to a rise in 
cAMP and subsequent protein kinase A activation. 
EP3 receptors are coupled to Gi proteins and activate 
phosphodiesterases that decrease cAMP, contributing to 
the resetting of the signaling[5]. In addition to this, PGs 
may control gene transcription through the activation 
of nuclear receptors of the peroxisome proliferators-
activating receptor family[6].
Two COX isoenzymes have been identified: COX-1, 
first purified from bovine vesicular glands, is ubiquitous 
and constitutively expressed in a wide variety of 
tissues where it accounts for the low and continuous 
PG synthesis required for tissue homeostasis; COX-2 is 
undetectable in tissues under normal conditions. Only 
few tissues have a constitutive COX-2 expression (i.e., 
placenta, testes, kidney and some neural tissues). 
However, a variety of extracellular and intracellular 
stimuli (inflammation, growth factors, hormones, 
reactive oxygen intermediates and oncogenes) can 
rapidly induce COX-2 expression in many cell types. 
Both COX isoenzymes share 61% primary sequence 
identity and exhibit similar kinetic properties with 
minimal biochemical differences. Despite the structural 
and kinetic similarities between COX-1 and COX-2, 
these close related enzymes carry out very different 
functions in tissues and organs due to their specific 
promoters, genes and mRNAs[7,8]. The second key 
enzyme that couples with COXs for the production of 
PGE2 is PGE2 synthase (PGES). Several isoforms of 
PGES have been characterized with specific enzymatic 
properties, cellular distribution and biochemical roles. 
Two main classifications for PGES have been defined: 
cytosolic (cPGES), and microsomal/membrane asso-
ciated (mPGES). cPGES is identical to the Hsp90-
associated protein 23. It is constitutively expressed 
in most cell types and is predominantly coupled with 
COX-1. However, the membrane associated mPGES 
is an inducible enzyme that is upregulated during 
inflammatory conditions. It has recently been shown 
that mPGES-1 is closely associated to the pathological 
expression of COX-2. Indeed, mPGES-1 deficiency 
reduces PGE2 synthesis and, in turn, attenuates tumor 
proliferation and invasion of several tumor cells[9].
The levels of PGE2 are the result of the fine tuning 
between the synthesis by mPGES and cPGES, and 
the degradation that is mainly due to the 15-hydro-
xyprostaglandin dehydrogenase (15-PGDH). 15-PGDH 
catalyzes the NAD-dependent oxidation of PGE2 (at 
C15) to generate the inactive PG 15-keto-PGE2. Animals 
lacking 15-PGDH exhibit an increase in tissue levels 
of PGE2. Moreover, despite a physiological action of 
15-PGDH in parturition and in the uterine tract, recent 
data propose a prominent role for 15-PGDH in oncologic 
processes[10].
COX-2 IN LIVER PATHOLOGY
Hepatocytes express receptors for most of the stimuli 
that induce COX-2 transcription in other cell types, 
including LPS, IL-1 and TNF-α. However, adult, but not 
fetal or neonatal hepatocytes do not express COX-2 in 
response to these pro-inflammatory molecules; only 
Kupffer, stellate and some hepatoma liver cells (not all) 
exhibit the capacity to express COX-2. In the case of 
hepatocytes, only under long-term aggression, COX-2 
is expressed due to the decrease in C/EBPα levels[11]. 
However, fetal hepatocytes, which contain negligible 
levels of C/EBPα compared to the adult counterparts, 
express COX-2 after pro-inflammatory challenge[12]. 
Interestingly, specific constitutive expression of 
COX-2 in liver protects against acute liver insults by 
combining an inhibition of apoptotic mechanisms in 
the hepatocytes, and promoting cell cycle progression 
and proliferation. To prove this, we analyzed several 
models of liver injury and compared the contribution 
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of a COX-2 transgene (COX-2-Tg) under the control 
of a specific hepatocyte promoter. In this regard, in 
the lipopolysaccharide and D-galactosamine treated 
mice (LPS/D-GalN), in the concanavalin A (ConA)-
induced hepatitis, and in the model of hepatocyte 
proliferation after partial hepatectomy (PH) the hepatic 
elevation of PGs due to the COX-2-Tg attenuates the 
injury induced by these stressors and accelerates 
proliferation after PH. Conversely, inhibition of COX-2 
with a selective COXIB ablates these protective effects. 
Interestingly, constitutive COX-2 expression in the 
liver results in an elevation of antiapoptotic genes as 
well as in the activation of proteins involved in cell 
survival, such as phospho-Akt and phospho-AMP-
kinase, after injury. Moreover, in the model of liver 
regeneration after PH, hepatocyte commitment to 
start replication is accelerated in COX-2-Tg mice due 
to the rapid elevation of PCNA, cyclin-D1 and E, all 
promoting cell cycle progression[13]. However, using a 
different COX-2-Tg animal model Han et al[14] found 
that COX-2 expression notably enhanced the injury 
after LPS challenge. These contradictory results are of 
interest in order to stress the relevance of the genetic 
background in animal studies. In fact, the molecular 
mechanisms described in our case for the protection, 
but also the opposite observation by the Han’s group 
can be explained in view of this circumstance (C57BL/6 
vs C57BL/6XDBA)[15]. Indeed, the wild-type animals 
of Han’s model did not showed a significant injury 
after LPS/D-GalN challenge as occurred in our C57BL/
6XDBA animals that displayed an acute apoptotic 
response, in the line reported by other groups using 
this injury model[15]. Figure 1 summarizes these data.
COX-2 AND NAFLD: NAS, NASH AND 
FIBROSIS
Non-alcoholic fatty liver disease (NAFLD) is defined as 
a broad clinical pathological entity that appears in the 
absence of alcohol abuse, but involving fat deposition 
in the hepatocyte (steatosis, NAS), and worsening 
to non-alcoholic steatohepatitis (NASH) and fibrosis, 
all conditions contributing to liver failure and in some 
cases, to hepatic carcinogenesis. NAFLD is recognized 
as the hepatic manifestation of metabolic syndrome 
and constitutes an important health problem that 
affects one-third of adults and an increasing number 
of children in developing countries[16]. The pathological 
definition of metabolic syndrome includes obesity, 
diabetes, dyslipidemia and hypertension among other 
symptoms. Around 90% of NAFLD patients have at 
least one symptom of metabolic syndrome and about 
33% have this full canonical profile. Although NAFLD 
is strongly associated with hyperlipidemia, diabetes 
mellitus, metabolic syndrome, obesity and insulin 
resistance (IR), its pathogenesis remains poorly 
understood and therapeutic options other than lifestyle 
modification by diet and exercise are limited.
Steatosis is defined as the presence of cytoplasmic 
TG droplets in more than 5% of the hepatocytes and is 
the result of an imbalance between the import and/or 
synthesis of fatty acids by hepatocytes and the rate 
of usage or export, leading to the formation of the 
characteristic lipid droplets. Hepatic steatosis (NAS) is 
the first manifestation of NAFLD, and is identified by 
the accumulation of triglycerides (TG) as lipid droplets 
in the cytoplasm of hepatocytes. NAS is often limited 
and reversible, but it can progress to chronic hepatic 
inflammation, insulin resistance, liver damage and 
NASH. A major issue is whether the progression to 
NAFLD is the cause or the consequence of IR[17]. In 
this regard, few studies determining hepatic IR at 
the gene expression level have been performed in 
NAFLD patients. However, the data available suggest 
that the insulin signaling pathway, using phospho-Akt 
and the transcription factor phospho-FoxO1 as read-
outs, shows an increase in NASH patients compared to 
healthy liver[18]. However, recent results from our group 
demonstrate that hepatic insulin signaling is decreased 
in NASH patients, and this process is associated 
with higher apoptotic rates and enhanced collagen 
deposition. Moreover, IR was not detected in NAS 
patients. Together, these data suggest that hepatic 
insulin signaling is preserved in NAS, at the time that 
point to fact that hepatic lipid overload precedes the 
impairment of hepatic insulin signaling[17].
The main difference between NAS and NASH is the 
occurrence of hepatocyte injury, including hepatocyte 
ballooning and increased cell death, infiltration 
of circulating inflammatory cells and enhanced 
parenchymal collagen deposition as morphologic 
signature of fibrosis. Intralobular inflammation in 
NASH includes the presence of a small number 
of lymphocytes, macrophages and neutrophils[18]. 
Inflammation in NASH involves the contribution of 
both parenchymal and non-parenchymal cells through 
the release of bioactive soluble mediators that finally 
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Figure 1  Main regulation and effects of cyclooxygenase-2 in liver. COX-2 
and PGE2 exert protection against many liver injuries and promote proliferation 
of hepatocytes and inhibition of apoptosis and necrosis of hepatic cells. The 
contribution to inflammation remains controversial depending on the moment of 
COX-2 expression.
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deficient (MCD) diet describing an increase in COX-2 
expression and the beneficial effects after celecoxib 
or nitro-aspirin treatment[24]. The interaction between 
PGE2, IL-6 and the IR in hepatocytes has been studied 
by Henkel et al[25,26] reporting that PGE2 enhanced 
fat accumulation and interrupted the intracellular 
signaling of insulin in hepatocytes through serine 
phosphorylation of IRS via EP3-receptor-dependent 
ERK1/2 activation. However, using COX-2-Tg mice we 
observed a protective role for COX-2 in liver injury 
induced by hyperglycemia in a streptozotocin diabetic 
mouse involving an increase in PI3K/Akt/AMPK 
survival pathway[27]. Recently, COX-2 was linked to 
cold-induced thermogenesis and this COX-2 activity 
in adipose tissue well correlates with the expression 
of specific differentiation markers of brown adipose 
tissue. Furthermore, COX-2 expression in white 
adipose tissue increased systemic energy expenditure 
and protected mice against HFD induced obesity[28]. 
Also, mice carrying a COX-2-Tg in hepatocytes 
are protected vs IR, adipose tissue proliferation/
differentiation and low-grade inflammation when fed 
HFD. In these COX-2-Tg mice, PGs are associated 
with increased systemic energy expenditure, higher 
thermogenesis, and enhanced fatty acid oxidation in 
the liver, favoring lipid clearance in the hepatocyte[29]. 
In addition to this, COX-2 represses specific miRNAs. 
One of them is miR-183, present in liver cells and 
that is repressed after COX-2 expression and/or in 
COX-2-Tg hepatocytes. Our group has demonstrated 
that this decrease in miR-183 is important in the 
preservation, and even potentiation of the insulin 
signaling pathway after different hepatic challenges[30]. 
Accordingly, COX-2 appears as an unexpected potential 
therapeutic strategy against obesity-associated 
metabolic dysfunction. In this regard, stable analogs 
of PGE2, such as 16,16dmPGE2, could be considered 
as therapeutic alternatives to prevent steatosis 
progression and/or IR. In fact, PGE2 and analogs are 
clinically used to ameliorate mild hypercholesterolemia 
among other liver pathologies[31,32].
The metabolic signals governing the transition 
from NAS to NASH are not well defined; however, the 
increase of lipid content in the hepatocyte contributes 
to an enhancement of oxidative stress, cell death and 
to create a low-grade pro-inflammatory ambience 
that sustains the initial lipid stress[33]. Again, the 
impact of PGE2 on this sequence from NAS to the 
establishment of NASH and the subsequent hepatic 
fibrosis remains controversial: in vivo studies in mice 
using selective COX-2 inhibitors showed a prevention 
in the progression to NASH, clearly pointing to COX-
2-dependent PGs as mediators of the progress[34,35]. 
However, the opposite approach, that is administration 
of PGE2, has been show to prevent HSC-dependent 
fibrogenesis and steatohepatitis[22,36,37]. Furthermore, 
Cheng et al[38] by using a liver COX-2-Tg mice (again in 
a genetic background distinct from C57BL/6), failed to 
show any contribution of these locally produced PGs to 
favor the recruitment of lymphoid and myeloid cells in 
the liver. Activated Kupffer and stellate cells contribute 
to cytokine expression during steatohepatitis. Among 
the pro-inflammatory cytokines involved in the 
progression to NASH, TNF-α and IL-6 seem to be very 
relevant[19]. Liver cells are also a target for adipose 
tissue generated factors. More specialized adipokines, 
such as adiponectin and leptin are also involved. 
Adiponectin was shown to block TNF-α activation 
of inflammatory genes, to decrease macrophage 
recruitment and function and to increase the synthesis 
of the anti-inflammatory cytokines IL-10 and IL-1Ra, 
displaying a beneficial effect on NAFLD in mice. Leptin 
appears to be a key factor in the formation of hepatic 
droplets due to a polarization in body fat distribution. 
Beside inflammation, stress signals, including oxidative 
stress and lipid peroxidation, lead to hepatocyte injury. 
Apoptotic cell death may also constitute an important 
component of disease progression. Oxidative stress 
appears to be a key factor in the pathogenesis of 
NASH as deduced by a significant increase of oxidative 
damage markers for lipids, proteins and DNA (MDA, 
4-HNE, nitro-tyrosine, and 8-OH-dG), as well as 
a decrease in the antioxidant capacity, including 
a reduction in catalase and glutathione reductase 
and a rise the GSSG/GSH ratio[20]. Despite the high 
antioxidant capacity of normal liver, hepatocytes sense 
oxidative stress as reflected by higher rates of cell 
death both by necrosis and apoptosis. Our results 
indicated that NASH, but not NAS hepatic samples, 
have lesser mRNA levels of Mcl-1 and Bcl-2. As a 
consequence of this, the active content of caspase 3 
and apoptosis were higher in NASH than in normal liver 
and in NAS patients[17]. NASH, in turn, can progress to 
fibrosis and cirrhosis. Hepatic stellate cells (HSCs) are 
the main contributors to extracellular matrix deposition 
and fibrosis as result of its activation in conditions of 
liver injury. Again, our data demonstrated an increase 
in the hepatic mRNA levels of COL1A in NASH and no 
changes in steatosis vs normal liver. In cirrhosis, HSCs 
are responsible of the type I collagen scar that replaces 
dying hepatocytes. Cirrhosis can ultimately progress 
to liver cancer; 4%-27% of individuals with NASH-
induced cirrhosis develop hepatocellular carcinoma 
(HCC).
Regarding COX-2 on these lipid and metabolic 
disorders, whereas some studies indicate that PGs 
may favor fat accumulation in hepatocytes and hence 
the progression from NAS to NASH, others provide 
evidence where PGE2 suppresses de novo lipogenesis. 
Therefore, the impact of PGE2 on the insulin-dependent 
changes in hepatic metabolism is controversial: Hsieh 
et al[21] reported that rats fed a fructose or high fat 
diet (HFD) and treated with COX-2 inhibitors improved 
muscle and fat IR[22]; however, in a different context 
Coll et al[23] reported that COX-2 inhibition exacerbates 
palmitate-induced inflammation and IR in skeletal 
muscle. There are also reports using murine models of 
NASH induced by high fat or methionine and choline-
Martín-Sanz P et al . Liver COX2 controversy
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NASH progression and steatohepatitis. In this regard, it 
is relevant to mention that PGE2 impairs the expression 
of pro-fibrogenic genes in human fat explants from 
obese individuals as well as antagonizes the TGF-
β-dependent fibrogenic activity in adipocytes[39]. 
In line with this, COX-2-Tg mice fed MCD diet are 
protected against NASH when compared with the Wt 
counterparts, essentially through a mechanism that 
involves a lesser recruitment of circulating immune 
cells and, as a consequence, a minor presence of 
pro-inflammatory factors in the liver, resulting in a 
minor activation of the pro-fibrogenic cells present in 
the tissue, such as HSCs. Furthermore, these COX-
2-Tg mice treated with a classic pro-fibrogenic insult 
as is CCl4 exhibited a significant protection against 
fibrosis progression as reflected by lower synthesis of 
hepatic collagen and accumulation of hydroxyproline 
when compared with the Wt controls[40]. Figure 2 
summarizes the main findings observed in the animal 
models carrying a COX-2 transgene.
COX-2 AND HCC
Hepatocellular carcinoma (HCC) is one of the most 
common solid cancers (30% of morbidity) and is very 
prevalent in cirrhotic patients. The incidence of HCC 
is increasing worldwide associated to hepatitis C virus 
(HCV) infection[41,42]. Moreover, hepatitis B virus (HBV) 
infection, and ambient risk factors (i.e., aflatoxin, 
alcoholic cirrhosis, etc.) contribute to HCC initiation 
and progression. Clinical diagnosis of HCC is difficult 
since no reliable serum markers have been clearly 
identified, and the therapeutic options for HCC are 
limited (i.e., sorafenib, cis-Pt, etc.). Despite the recent 
introduction of potent preventive chemotherapeutic 
protocols the study of the molecular mechanisms 
leading to human hepatocarcinogenesis remains an 
area of intense research in order to understand the 
progression from NASH and cirrhosis to HCC. Gene 
expression profiling and proteomic approaches have 
contributed to identify specific signatures that can 
be used for the identification of proteins that are 
differentially expressed between normal and liver 
tumors in an attempt to define new and more selec-
tive biomarkers for HCC. Integrative transcriptome 
analysis reveals three molecular HCC subclasses, 
each correlated with different clinical parameters and 
serum markers[42]. Like in other cancers, the key event 
driving liver carcinogenesis is the development of 
simultaneous deregulated proliferation and reduced 
cell death. Work by different groups have characterized 
molecular signatures implicated in tumorigenesis: 
(1) receptor tyrosine kinase pathways; (2) Wnt/
β-catenin signaling pathway; (3) ubiquitin/proteasome 
degradation pathway; (4) epigenetic DNA methylation 
and histone deacetylation pathways; (5) the PI3K/Akt/
mTOR pathway; (6) angiogenic pathways; and (7) 
telomerase activity[43]. 
Regarding the involvement of COX-2-derived PGs 
in hepatocarcinogenesis it should be mentioned that 
selective COX-2 inhibitors have proved to inhibit HCC 
cell growth in vitro and in xenograft animal models. 
As previously mentioned, COX-2 expression in liver 
appears to be restricted to very special conditions. In 
fact, COX-2 is transiently expressed in regenerating 
liver after PH or after challenge with potent hepatotoxic 
molecules, such as thioacetamide among other[44,45]. In 
addition to this, COX-2 expression has been observed 
in animal models of cirrhosis, in human and several (but 
not all) mouse hepatoma cell lines, after HBV or HCV 
↓ Insulin 
resistance
↑ Proliferation
↑ Angiogenesis
    
↑ Thermogenesis/
Energy 
expenditure
↓ Adiposity 
↓ Steatosis
↓ Inflammation
↓ Apoptosis↓ Fibrosis
COX-2-Tg 
(↑ PGE2)
Figure 2  Mice carrying a COX-2 transgene in hepatocytes have elevated PGE2 and are protected against hepatic insults. PGE2 produced by hepatic COX-2 
has specific effects in liver against inflammation, steatosis, fibrosis and apoptosis. At the systemic level protection against insulin resistance and adiposity is observed, 
whereas angiogenesis and thermogenesis are enhanced.
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infection and in human HCC[46-50]. However, although 
COX-2 expression is detected in early phases of HCC, 
contradictory observations have been published 
regarding the nature of the cells expressing the 
enzyme (both in normal hepatocytes and in hepatoma 
cells), the role of this expression pattern and the 
molecular mechanisms by which COX-2-dependent 
PGs contribute and/or induce tumorigenesis. Inte-
restingly, work from our group[51] has shown that 
COX-2 expression is not sufficient to exacerbate 
malignant transformation after administration of 
chemical hepatocarcinogens. Even more, progression 
of liver oncogenesis in a well-established model of 
HCC (the c-myc and TGF-α double transgenic mice), is 
not affected by COX-2 expression[52]. However, COX-2 
expression in this model facilitated the development 
of preneoplastic foci but failed to promote malignant 
transformation, probably as result of the contribution of 
COX-2-derived PGs to inhibit apoptosis and to provide 
an anti-inflammatory environment, these conditions 
opposing the initiation of the early phases of HCC. 
Using COX-2-Tg hepatocyte cell lines we also showed 
elevated oxidative stress and ROS accumulation after 
chemical hepatocarcinogenesis, together with an 
important decrease in the levels of GSH and higher 
levels of 8-OHdG. Moreover, a moderate activation 
of JNK, Erk and p38 was detected in COX-2-Tg cells, 
and COX-2 favored the growth of cell implants in 
nude mice, probably through the sustained activation 
of Akt and JNK-c-Jun survival pathways. Recently, it 
has been shown that PGE2 is able to increase c-Myc 
levels through the activation of the EP4R/GS/AC/
cAMP/PKA/CREB cascade that favors HCC growth and 
invasion of these cells, contributing PGE2 in this way to 
hepatocellular carcinogenesis[53].
Genetic deletion of 15-PGDH, the enzyme which 
degrades PGE2 to an inactive 15-keto- PGE2, leads 
to increased tissue levels of PGE2. We have shown 
that 15-PGDH is repressed in human HCC cell lines, 
together with elevation of COX-2, in chemical and 
genetic murine models of HCC and in human HCC 
biopsies. Moreover, transfection of HCC cells with 
15-PGDH induces apoptosis and attenuates the 
growth of these cells when implanted in nude mice; 
at the same time, transfection with siRNA specific 
for 15-PGDH promoted tumor growth indicating that 
the balance between COX-2 and 15-PGDH activities 
are relevant in the hepatocarcinogenic process[54]. 
Interestingly, 15-PGDH not only plays a protective 
role by decreasing PGE2 levels, but also the 15-keto-
PGE2 generated has been shown to activate PPARγ. 
Indeed, activated PPARγ by 15-keto-PGE2 favors the 
interaction with the p21(WAF1/Cip1) promoter, which 
in turn results in p21 expression and association with 
cyclin-dependent kinase 2 (CDK2), CDK4 and PCNA[55]. 
Altogether, the results of higher pulmonary metastatic 
incidence of HCC in COX-2-Tg mice and the promotion 
and migration of HCC cells induced by PGE2[48] suggest 
that COX-2 might be involved in the expansion 
and metastatic phase of HCC. COX-2 exerts pro-
metastatic effects on cancer stem cells mediated partly 
through regulation of PDCD4 and PTEN expression[56]. 
Moreover, PGE2 could upregulate the expression 
level of Snail, an inducer of epithelial-mesenchymal 
transition a key player in HCC invasion and metastasis, 
through the EP2/Src/EGFR/Akt/mTOR pathway[57].
Besides the murine models, we have investiga-
ted whether a correlation exists between COX-2 ex-
pression and different grades of methylation at the 5’
region of the COX-2 gene in hepatoma cell lines and 
in HCC. We also analyzed the acetylation signatures 
of the COX-2 promoter and the effects of inhibitors 
of histone deacetylase (HDAC) on COX-2 expression. 
Our results indicate that the low COX-2 expression 
in some hepatoma cell lines and HCC is associated 
with promoter hypermethylation of COX-2. Histone 
deacetylation and treatment with demethylating 
agents or HDAC inhibitors restored the expression 
of COX-2[41]. Interestingly enough, COX-2 mRNA 
levels were higher in the non-tumoral liver tissue 
than in HCC; moreover, inverse correlations between 
COX-2 levels and the differentiation grade of HCC 
were observed. Clinical studies showed a reduction 
of survival in patients when COX-2 expression 
decreased due to promoter hypermethylation and 
histone H3 hypoacetylation. Indeed, Giannitrapani 
et al[47] reported a dispersed range of COX-2 expres-
sion in human HCC, from absence of expression in 
undifferentiated areas to a robust expression in well 
differentiated tissue. Moreover, COX-2 expression was 
significantly lower in HCC than in NASH. However, a 
recent meta-analysis study revealed that the presence 
of COX-2 in HCC is associated with stages of decreased 
overall and disease-free survival and represents a 
worse prognosis[57]. Recent studies in different cancer 
cells point out to a COX-dependent tumor growth 
through evasion of immunity and tumor-promoting 
inflammation. Pre-clinical data indicate that inhibition 
of COX-2 in breast or colorectal cancer cells favors 
the activation of immune mechanisms against cancer 
cells, reinforcing the immunosuppressive role of 
PGs[58]. Moreover, since HSCs are important mediators 
of immunosuppression and in the progress of HCC, 
it is suggested that they contribute to HCC through 
the recruitment of immunosuppressive cells, mainly 
myeloid-derived suppressor cells and regulatory T 
cells, through a mechanism involving the COX-2-
PGE2-EP4 pathway[59]. As a summary of these data, 
controversy exists in the literature regarding the 
precise role of COX-2 and PGE2 in the development of 
HCC.
CONCLUSION
The assessment of the role of COX-2 in hepatic 
diseases, ranging from NASH to HCC, constitutes a 
field in which controversy exists probably because 
of the use of different experimental models and 
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specific temporary guidelines of the time-dependent 
contribution of COX-2-derived metabolites to the 
onset of these hepatic dysfunctions. Since potent and 
selective inhibitors of COX-2 exist, but also stable 
PGE2 analogues to be used in therapy, unraveling the 
precise contribution of this enzyme and its products 
is crucial for the prevention of the progression of 
liver dysfunctions and it appears to be a useful 
approach for managing the patients. Efforts to identify 
biomarkers providing indications for the correct use 
of these therapeutic tools are essential to underline 
new intervention protocols based on COX-2 and 
prostaglandin targeting. 
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